Israel's Chemomab Q4 net loss narrows on lower R&D spend

Chemomab Therapeutics

19/03/2026 12:09

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * Israel biotech developer's Q4 and full-year operating expenses declined 
    * Net loss for Q4 and full year narrowed compared to 2024
    * Company achieved FDA alignment on Phase 3 trial design for nebokitug in PSC

    
    Outlook
  
    * Chemomab expects cash runway to last through end of Q1 2027
    * Chemomab evaluating additional indications for nebokitug based on preclinical efficacy signals

    
    Result Drivers
  
    * LOWER R&D SPENDING - Co said decrease in R&D expenses was due to completion of nebokitug Phase 2 PSC trial

    
Company press release:  ID:nGNX5Rxt1g 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4                  $1.97      
 Operatin            mln       
 g                             
 Expenses                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the biotechnology & medical research peer group is "buy."
    * Wall Street's median 12-month price target for Chemomab Therapeutics Ltd is $17.50, about 775% above its March 18 closing price of $2.00

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)